Mitsuo Sato

List of Publications by Year in Descending Order

83 papers	5,430 citations	34 h-index	73 g-index
87 ext. papers	5,985 ext. citations	6.1 avg, IF	4.66 L-index

#	Paper	IF	Citations
83	Resistance to mutant KRAS-induced senescence in a hTERT/Cdk4-immortalized normal human bronchial epithelial cell line.. *Experimental Cell Research*, **2022**, 113053	4.2	
82	Hurdles for the wide implementation of photoimmunotherapy. *Immunotherapy*, **2021**, 13, 1427-1438	3.8	2
81	Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. *Endocrine Journal*, **2021**, 68, 613-620	2.9	3
80	Oxytocin receptor is a promising therapeutic target of malignant mesothelioma. *Cancer Science*, **2021**, 112, 3520-3532	6.9	3
79	Optimization and validation of a highly sensitive method for determining glyphosate in human urine by solid-phase extraction and liquid chromatography with tandem mass spectrometry: a methodological study. *Environmental Health and Preventive Medicine*, **2020**, 25, 83	4.2	2
78	, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer. *Cancer Investigation*, **2020**, 38, 240-249	2.1	2
77	Immortalized normal human lung epithelial cell models for studying lung cancer biology. *Respiratory Investigation*, **2020**, 58, 344-354	3.4	8
76	Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients. *PLoS ONE*, **2020**, 15, e0241422	3.7	2
75	Risk factors for pulmonary infection after diagnostic bronchoscopy in patients with lung cancer. *Nagoya Journal of Medical Science*, **2020**, 82, 69-77	0.7	
74	Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer. *Oncology Letters*, **2020**, 19, 3617-3626	2.6	4
73	Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer. *Cancer Investigation*, **2020**, 38, 424-430	2.1	0
72	Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. *Clinical Lung Cancer*, **2020**, 21, 273-280.e4	4.9	12
71	Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients **2020**, 15, e0241422		
70	Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients **2020**, 15, e0241422		
69	Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients **2020**, 15, e0241422		
68	Development of an immuno-wall device for the rapid and sensitive detection of EGFR mutations in tumor tissues resected from lung cancer patients **2020**, 15, e0241422		
67	Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. *Lung Cancer*, **2019**, 127, 169-171	5.9	14

66	Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. *Lung Cancer*, **2019**, 128, 20-25	5.9	1
65	A 65-nm CMOS Fully Integrated Analysis Platform Using an On-Chip Vector Network Analyzer and a Transmission-Line-Based Detection Window for Analyzing Circulating Tumor Cell and Exosome. *IEEE Transactions on Biomedical Circuits and Systems*, **2019**, 13, 470-479	5.1	8
64	Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. *Biochemical and Biophysical Research Communications*, **2018**, 495, 2344-2349	3.4	28
63	Pseudomembranous Invasive Tracheobronchial Aspergillosis with Fulminant Hepatitis and Hemophagocytic Syndrome. *Internal Medicine*, **2018**, 57, 2371-2375	1.1	3
62	Pulmonary Malignancies (1): Lung Cancer What Are the Roles of Genetic Factors in Lung Cancer Pathogenesis?. *Respiratory Disease Series*, **2018**, 193-206	0.2	
61	Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer. *European Geriatric Medicine*, **2018**, 9, 255-262	3	2
60	An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. *Internal Medicine*, **2018**, 57, 3429-3432	1.1	5
59	eIF2a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. *Cancer Science*, **2018**, 109, 1843-1852	6.9	13
58	Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty. *Internal Medicine*, **2018**, 57, 1429-1432	1.1	
57	Identification of proteasomal catalytic subunit PSMA6 as a therapeutic target for lung cancer. *Cancer Science*, **2017**, 108, 732-743	6.9	11
56	ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. *Journal of Clinical Investigation*, **2016**, 126, 3219-35	15.9	183
55	Successful Desensitization Therapy with Crizotinib for Disease-recurrence of Resected Lung Adenocarcinoma. *Japanese Journal of Lung Cancer*, **2016**, 56, 215-218	0.1	
54	Factors Affecting the Diagnostic Yield of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in Peripheral Lung Cancer. *Internal Medicine*, **2016**, 55, 1705-12	1.1	25
53	miRNAs in Transitions: EMT, MET, and EndoMT **2015**, 893-915		0
52	Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. *Cancer Medicine*, **2015**, 4, 551-64	4.8	57
51	Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. *PLoS ONE*, **2015**, 10, e0134842	3.7	11
50	Prospective analysis of efficacy and safety of an individualized-midazolam-dosing protocol for sedation during prolonged bronchoscopy. *Respiratory Investigation*, **2014**, 52, 153-9	3.4	15
49	Protective effects of intratracheally administered quercetin on lipopolysaccharide-induced acute lung injury. *Respiratory Research*, **2014**, 15, 150	7.3	60

48	TIMELESS is overexpressed in lung cancer and its expression correlates with poor patient survival. *Cancer Science*, **2013**, 104, 171-7	6.9	37
47	Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. *Oncogene*, **2013**, 32, 4034-42	9.2	42
46	Aqueous fraction of Sauropus androgynus might be responsible for bronchiolitis obliterans. *Respirology*, **2013**, 18, 340-7	3.6	6
45	Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. *Molecular Cancer Research*, **2013**, 11, 638-50	6.6	135
44	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. *Cancer Research*, **2013**, 73, 2428-34	10.1	126
43	Endobronchial ultrasound transbronchial needle aspiration in older people. *Geriatrics and Gerontology International*, **2013**, 13, 986-92	2.9	12
42	NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6524-9	11.5	54
41	Echoic features of lymph nodes with sarcoidosis determined by endobronchial ultrasound. *Internal Medicine*, **2013**, 52, 1473-8	1.1	17
40	Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. *International Journal of Cancer*, **2012**, 130, 1733-44	7.5	65
39	Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. *Respirology*, **2012**, 17, 1048-59	3.6	69
38	Transient but not stable ZEB1 knockdown dramatically inhibits growth of malignant pleural mesothelioma cells. *Annals of Surgical Oncology*, **2012**, 19 Suppl 3, S634-45	3.1	6
37	STIM1 regulates platelet-derived growth factor-induced migration and Ca2+ influx in human airway smooth muscle cells. *PLoS ONE*, **2012**, 7, e45056	3.7	36
36	Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells. *Molecular Carcinogenesis*, **2012**, 51, 400-10	5	29
35	The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. *International Journal of Cancer*, **2012**, 131, 2820-31	7.5	50
34	Nongenomic effects of fluticasone propionate and budesonide on human airway anion secretion. *American Journal of Respiratory Cell and Molecular Biology*, **2012**, 47, 645-51	5.7	3
33	Pivotal role of epithelial cell adhesion molecule in the survival of lung cancer cells. *Cancer Science*, **2011**, 102, 1493-500	6.9	18
32	Capsaicinoids regulate airway anion transporters through Rho kinase- and cyclic AMP-dependent mechanisms. *American Journal of Respiratory Cell and Molecular Biology*, **2011**, 45, 684-91	5.7	4
31	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. *Molecular Cancer Therapeutics*, **2011**, 10, 336-46	6.1	123

30	Pleural plaque profiles on the chest radiographs and CT scans of asbestos-exposed Japanese construction workers. *Industrial Health*, **2011**, 49, 626-33	2.5	9
29	Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. *Cancer Letters*, **2010**, 296, 216-24	9.9	125
28	Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. *Oncogene*, **2008**, 27, 3635-40	9.2	168
27	Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. *Cancer Research*, **2008**, 68, 1119-27	10.1	101
26	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 14112-7	11.5	103
25	PIK3CA mutations and copy number gains in human lung cancers. *Cancer Research*, **2008**, 68, 6913-21	10.1	339
24	Molecular Basis of Lung Cancer **2008**, 397-407		
23	Characterizing the cancer genome in lung adenocarcinoma. *Nature*, **2007**, 450, 893-8	50.4	900
22	Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. *Cancer Research*, **2007**, 67, 5267-74	10.1	130
21	A translational view of the molecular pathogenesis of lung cancer. *Journal of Thoracic Oncology*, **2007**, 2, 327-43	8.9	237
20	EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. *American Journal of Respiratory Cell and Molecular Biology*, **2007**, 37, 578-88	5.7	27
19	Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells. *Reproductive Sciences*, **2007**, 14, 20-8	3	33
18	Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized. *Cancer Research*, **2007**, 67, 7695-702	10.1	37
17	EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. *Cancer Research*, **2007**, 67, 4665-70	10.1	82
16	M10-04: Telomerase immortalized human bronchial epithelial cells (HBECs) have stem cell characteristics. *Journal of Thoracic Oncology*, **2007**, 2, S181-S182	8.9	0
15	A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. *PLoS Medicine*, **2006**, 3, e486	11.6	191
14	Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. *Cancer Research*, **2006**, 66, 2116-28	10.1	223
13	High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. *Cancer Research*, **2006**, 66, 4198-207	10.1	138

12	Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. *Cancer Research*, **2006**, 66, 9601-8	10.1	174
11	The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. *Oncogene*, **2005**, 24, 2735-8	9.2	14
10	High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. *Cancer Research*, **2005**, 65, 11478-85	10.1	124
9	Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. *Cancer Research*, **2004**, 64, 4277-85	10.1	156
8	Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. *Cancer Research*, **2004**, 64, 9027-34	10.1	498
7	Pulmonary cryptococcosis with a solitary focal ground-glass opacity on high-resolution computed tomography. *Internal Medicine*, **2004**, 43, 117-9	1.1	4
6	Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer. *Oncogene*, **2003**, 22, 7243-6	9.2	54
5	Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor. *Cancer Genetics and Cytogenetics*, **2002**, 137, 33-42		19
4	The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines. *Oncogene*, **2002**, 21, 4822-9	9.2	73
3	Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. *Cancer Chemotherapy and Pharmacology*, **2001**, 48, 481-7	3.5	11
2	Genetic alteration of the beta-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. *Oncogene*, **2001**, 20, 4249-57	9.2	92
1	Infrequent mutation of the hBUB1 and hBUBR1 genes in human lung cancer. *Japanese Journal of Cancer Research*, **2000**, 91, 504-9		58